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Ovarian cancer is the most lethal gynecologic malignancy in both African-American and white women. Although
prevalences of many ovarian cancer risk factors differ markedly between African Americans and whites, there has
been little research on how the relative contributions of risk factors may vary between racial/ethnic groups. Using
data from a North Carolina case-control study (1999–2008), the authors conducted unconditional logistic regres-
sion analyses to calculate odds ratios and 95% confidence intervals for ovarian cancer risk factors in African-
American (143 cases, 189 controls) and white (943 cases, 868 controls) women and to test for interactions by race/
ethnicity. They also calculated attributable fractions within each racial/ethnic group for the modifiable factors of
pregnancy, oral contraceptive use, tubal ligation, and body mass index. Many risk factors showed similar relations
across racial/ethnic groups, but tubal ligation and family history of breast or ovarian cancer showed stronger
associations among African Americans. Younger age at menarche was associated with risk only in white women.
Attributable fractions associated with tubal ligation, oral contraceptive use, and obesity were markedly higher for
African Americans. The relative importance of ovarian cancer risk factors may differ for African-American women,
but conclusions were limited by the small sample. There is a clear need for further research on etiologic factors for
ovarian cancer in African-American women.
African Americans; case-control studies; ovarian neoplasms
Abbreviations: BMI, body mass index; CI, confidence interval.
Ovarian cancer is the eighth most common cancer among
both white and African-American women and the fifth most
common cause of cancer death in the United States (1, 2).
African-American women have lower incidence rates than
white women (10.1 cases/100,000 women vs. 14.1 cases/
100,000 women) but poorer 5-year survival (1). Despite
the importance of ovarian cancer as a major cause of mor-
bidity and mortality, there has been very little research on
ovarian cancer among African Americans. Only 2 published
papers have focused on risk factors for ovarian cancer
among African Americans: 1 on a case-control study with
84 cases (3) and 1 on a multicenter analysis of 7 case-control
studies involving 110 cases (4). Both of these reports had
findings that were consistent with the major reproductive
risk factors identified in white women, including inverse
associations with parity and oral contraceptive use (3, 4),
but some racial/ethnic differences were noted, including the
absence of a protective effect for breastfeeding and no in-
creased risk associated with a family history of ovarian
cancer among African Americans (3).
As has been reported by John et al. (4), Ness et al. (3), and
other authors (5–12), the prevalence of many factors asso-
ciated with risk of ovarian cancer varies markedly between
African Americans and whites. African-American women
tend to have a greater number of pregnancies (5, 7), a higher
prevalence of tubal ligation (6), a lower prevalence of en-
dometriosis (9), and less use of menopausal hormones
(5, 10), all of which would be associated with a lower in-
cidence of ovarian cancer. They also tend to have an earlier
age at menarche (11), are more likely to be obese (12), and
are less likely to breastfeed (8), which could contribute to
higher risk of ovarian cancer. Because most epidemiologic
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studies of ovarian cancer have enrolled very few African-
American women, there is little information on the relative
importance of these risk factors among African-American
women as compared with white women and the extent to
which differences in the prevalence of established risk fac-
tors can explain the lower incidence of ovarian cancer
among African Americans.
In this paper, we use data from the North Carolina Ovar-
ian Cancer Study to compare risk factors for ovarian cancer
among African-American and white women. We also cal-
culate population attributable fractions for risk factors that
are both modifiable and show considerable racial/ethnic dif-
ferences in prevalence to evaluate the relative proportions of
cases in African-American and white women that are asso-
ciated with these factors.
MATERIALS AND METHODS
TheNorth Carolina Ovarian Cancer Study was a population-
based, case-control study of epithelial ovarian cancer that
was conducted in a 48-county region of North Carolina
between 1999 and 2008. Newly diagnosed cases of epithe-
lial ovarian cancer were identified through the North Carolina
Central Cancer Registry using a rapid case ascertainment
system. Pathology reports for eligible cases were sent to the
study office at Duke University Medical Center, and consent
to contact the women was requested from the treating physi-
cians. Eligible cases were aged 20–74 years at diagnosis, had
no prior history of ovarian cancer, resided in the study area,
and were cognitively able to give consent and to complete an
interview in English. All cases underwent standardized his-
topathologic review by the study pathologist for confirmation
of the diagnosis. Control women were frequency-matched by
age and race/ethnicity to the cases and were recruited from
the same geographic region using list-assisted random digit
dialing. The eligibility criteria were the same as those for the
cases; in addition, the controls could not have had a bilateral
oophorectomy.
The response rate among the cases was 66.5%, with non-
participation being due to death (4.0%), debilitating illness
(2.6%), physician refusal (4.7%), patient refusal (11.5%), or
an inability to locate the patient (10.7%). Among potential
controls, screening for eligibility could not be completed for
14% of phone numbers. Seventy-three percent of potential
controls who passed eligibility screening agreed to be sent
information about the study, and 60.1% of those consented
to be in the study. Nonparticipation was due to refusal
(27.4%) or an inability to contact the person (8.8%). Re-
sponse rates were lower for African Americans than for
whites (56.6% and 68.3%, respectively, for cases and
49.7% and 63.7%, respectively, for controls).
A total of 1,114 cases were enrolled, of whom 943 (84.6%)
were white, 143 (12.8%) were African-American, and 28
(2.5%)were of other races/ethnicities. Among the 1,086 con-
trols, 868 (79.9%) were white, 189 (17.4%) were African-
American, and 29 (2.7%) were of other races/ethnicities. The
analyses in this report were limited to women whose self-
reported race/ethnicity was either white or African-American.
The study protocol was approved by the Duke University
Medical Center Institutional Review Board and by the human
subjects committees at the North Carolina Central Cancer
Registry and each hospital where cases were identified.
Nurse-interviewers conducted in-person visits at which
they obtained written informed consent, administered a 90-
minute questionnaire, drew a blood sample, and performed
anthropometric measurements (height, weight, and waist and
hip circumferences). Information obtained with the question-
naire included family history of cancer; menstrual character-
istics such as age at menarche and cycle length; reproductive
history, including age at each pregnancy, pregnancy duration
and outcome, and duration of breastfeeding; type, timing, and
duration of hormone and contraceptive use; and lifestyle
characteristics such as smoking history, alcohol consumption
during the 5 years before interview, and physical activity.
A life-events calendar, which marked milestones such as
marriages and births, was used to aid recall of reproductive
history and hormone use. Pictures of oral contraceptives,
menopausal hormones, and certain other medications were
also used to assist with recall.
Statistical analysis
Chi-squared analyses were used to compare clinical and
histologic characteristics of cases between African Americans
Table 1. Clinical and Histologic Characteristics of Epithelial
Ovarian Cancer Cases in African-American and White Women,




No. % No. %
All cases (n ¼ 943) (n ¼ 143)
Invasive tumor 746 79.4 111 77.6 0.64
Low-malignant-potential
tumor
194 20.6 32 22.4
Missing data 3 0
Invasive cases only (n ¼ 746) (n ¼ 111)
Histologic type
Serous 419 56.2 67 60.4 0.05
Clear-cell 82 11.0 2 1.8
Endometrioid 116 15.5 19 17.1
Mucinous 39 5.2 6 5.4
Other 90 12.1 17 15.3
Stage
I or II 245 33.1 25 22.7 0.04
III or IV 496 66.9 85 77.3
Missing data 5 1
Grade
Well-differentiated 93 12.9 18 16.8 0.12
Moderately
differentiated
197 27.2 36 33.6
Poorly differentiated
or undifferentiated
433 59.9 53 49.5
Missing data 23 4
a P values were derived from chi-squared analyses.
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Table 2. Characteristics of Invasive Epithelial Ovarian Cancer Cases and Controls, by Race/Ethnicity, North











(n 5 189) ORa 95% CI
No. % No. % No. % No. %
Age, years
20–39 38 5.1 81 9.3 11 9.9 22 11.6
40–49 136 18.2 170 19.6 23 20.7 46 24.3
50–59 239 32.0 261 30.1 37 33.3 67 35.4
60–69 232 31.1 240 27.6 31 27.9 40 21.2
70–74 101 13.5 116 13.4 9 8.1 14 7.4
Age at menarche, years
<12 181 24.4 157 18.2 1.00 Referent 28 25.5 53 28.0 1.00 Referent
12 562 75.6 708 81.8 0.67 0.53, 0.86 82 74.5 136 72.0 1.08 0.63, 1.85
Missing data 3 3 1 0
No. of pregnancies 11
0 120 16.1 87 10.0 1.00 Referent 14 12.6 11 5.8 1.00 Referent
1–2 319 42.8 348 40.1 0.62 0.45, 0.85 31 27.9 71 37.6 0.34 0.14, 0.82
3 307 41.2 433 49.9 0.45 0.33, 0.62 66 59.5 107 56.6 0.44 0.19, 1.05
P-trend <0.0001 0 0 0.25
Age at first pregnancy, years
<20 173 27.6 202 25.9 1.00 Referent 56 58.3 94 52.8 1.00 Referent
20–24 276 44.1 333 42.7 0.93 0.72, 1.21 30 31.3 52 29.2 0.98 0.56, 1.72
25–29 137 21.9 151 19.4 1.09 0.80, 1.49 8 8.3 19 10.7 0.73 0.30, 1.79
30–34 31 5.0 79 10.1 0.50 0.31, 0.79 1 1.0 10 5.6 0.18 0.02, 1.45
35 9 1.4 14 1.8 0.77 0.33, 1.84 1 1.0 3 1.7 0.65 0.07, 6.45
Missing data 120 89 15 11
P-trend 0.0004 0.15
Age at last pregnancy, years
<20 19 3.0 18 2.3 1.00 Referent 11 11.7 13 7.3 1.00 Referent
20–24 134 21.4 147 18.9 0.79 0.39, 1.57 24 25.5 35 19.8 0.82 0.31, 2.14
25–29 233 37.3 258 33.1 0.76 0.38, 1.49 25 26.6 51 28.8 0.57 0.22, 1.45
30–34 161 25.8 230 29.5 0.60 0.30, 1.18 22 23.4 48 27.1 0.54 0.21, 1.40
35 78 12.5 126 16.2 0.53 0.26, 1.08 12 12.8 30 16.9 0.43 0.15, 1.23
Missing data 121 89 17 12
P-trend <0.0001 0.04
Ever breastfeeding
No 521 69.8 542 62.4 1.00 Referent 75 67.6 135 71.4 1.00 Referent
Yes 225 30.2 326 37.6 0.73 0.59, 0.90 36 32.4 54 28.6 1.16 0.69, 1.93
Missing data 0 0 0 0
Tubal ligation
No 559 75.0 579 66.8 1.00 Referent 77 69.4 93 49.2 1.00 Referent
Yes 186 25.0 288 33.2 0.68 0.54, 0.84 34 30.6 96 50.8 0.43 0.26, 0.71
Missing data 1 1 0 0
Duration of oral contraceptive
use, years
Never use 244 34.5 239 28.3 1.00 Referent 47 43.9 58 32.2 1.00 Referent
<1 99 14.0 92 10.9 1.09 0.77, 1.52 15 14.0 14 7.8 1.36 0.59, 3.14
1–<5 166 23.4 228 27.0 0.75 0.57, 0.99 24 22.4 57 31.7 0.54 0.28, 1.04
5 199 28.1 285 33.8 0.73 0.55, 0.96 21 19.6 51 28.3 0.53 0.27, 1.03
Missing data 38 24 4 9
Table continues
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and whites. Unconditional logistic regression analyses were
used to calculate age-adjusted and multivariable-adjusted
odds ratios and 95% confidence intervals separately for each
racial/ethnic group. Variables included in the race/ethnicity-
specific multivariable models were age, age at menarche,
number of pregnancies, duration of oral contraceptive use,
history of tubal ligation, family history of breast and ovarian
cancer, and body mass index (BMI; weight (kg)/height
(m)2). The variables included in multivariable models were












(n 5 189) ORa 95% CI
No. % No. % No. % No. %
Use of menopausal
hormones
No 276 37.0 456 52.6 1.00 Referent 75 68.8 148 78.3 1.00 Referent
Yes 470 63.0 411 47.4 1.85 1.50, 2.28 34 31.2 41 21.7 1.54 0.90, 2.66
Missing data 0 1 2 0
Hysterectomy
No 537 72.2 667 76.9 1.00 Referent 82 73.9 145 76.7 1.00 Referent
Yes 207 27.8 200 23.1 1.22 0.97, 1.54 29 26.1 44 23.3 1.07 0.61, 1.87
Missing data 2 1 0 0
History of infertility
No 651 87.3 783 90.2 1.00 Referent 102 91.9 175 92.6 1.00 Referent
Yes 95 12.7 85 9.8 1.38 1.01, 1.89 9 8.1 14 7.4 1.13 0.47, 2.73
Missing data 0 0 0 0
History of endometriosis
No 650 87.7 793 92.3 1.00 Referent 109 98.2 184 98.4 1.00 Referent
Yes 91 12.3 66 7.7 1.76 1.26, 2.46 2 1.8 3 1.6 1.16 0.19, 7.08
Missing data 5 9 0 2
First-degree family history
of breast or ovarian
cancer
No 582 78.1 720 83.1 1.00 Referent 69 62.2 159 84.1 1.00 Referent
Yes 163 21.9 146 16.9 1.33 1.04, 1.71 42 37.8 30 15.9 3.15 1.82, 5.45
Missing data 1 2 0 0
Talc use
No 328 59.6 325 61.0 1.00 Referent 45 54.2 75 56.0 1.00 Referent
Yes 222 40.4 208 39.0 1.04 0.82, 1.33 38 45.8 59 44.0 1.19 0.68, 2.09
Missing data 196 335 28 55
Body mass indexb 1 year
before diagnosis or
interview
<25 312 43.3 369 43.7 1.00 Referent 17 15.9 31 17.1 1.00 Referent
25–<30 212 29.4 256 30.3 0.96 0.76, 1.22 26 24.3 58 32.0 0.84 0.39, 1.78
30–<35 114 15.8 124 14.7 1.08 0.80, 1.45 22 20.6 43 23.8 0.94 0.43, 2.07
35 83 11.5 95 11.3 1.04 0.75, 1.45 42 39.3 49 27.1 1.62 0.79, 3.35
Missing data 25 24 4 8
Height, m
<1.6 195 26.2 242 27.9 1.00 Referent 25 22.7 57 30.2 1.00 Referent
1.6–<1.7 430 57.8 483 55.8 1.13 0.90, 1.42 64 58.2 102 54.0 1.48 0.84, 2.62
1.7 119 16.0 141 16.3 1.11 0.81, 1.51 21 19.1 30 15.9 1.74 0.83, 3.65
Missing data 2 2 1 0
Abbreviations: CI, confidence interval; OR, odds ratio.
a Adjusted for age.
b Weight (kg)/height (m)2.
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factors for ovarian cancer as well as BMI, because of the
pronounced racial/ethnic differences in the prevalence of
obesity. We also conducted multivariable analyses limited
to parous women that included all of the above variables
plus breastfeeding. Finally, to test for interactions, we fitted
models for women of both racial/ethnic groups combined
which included a term for race/ethnicity and product terms
for race/ethnicity 3 age at menarche, race/ethnicity 3
breastfeeding, and race/ethnicity 3 family history of breast
or ovarian cancer.
Population attributable fractions were calculated using
the method described by Bruzzi et al. (13) for the potentially
modifiable factors tubal ligation (yes vs. no), oral contra-
ceptive use (1 year vs. <1 year), history of pregnancy
(ever vs. never), and BMI (<30 vs. 30). For these anal-
yses, the reference categories were assigned to the lower risk
category (i.e., having had a tubal ligation, oral contraceptive
use for 1 year, ever being pregnant, and BMI <30) so the
attributable fraction could be interpreted as the proportion of
cases that theoretically could be eliminated if all women in
the population were shifted to the low risk category.
RESULTS
The tumor characteristics of the ovarian cancer cases are
presented in Table 1 by race/ethnicity. The proportions of
cases that were invasive were similar for African Americans
and whites (78% and 79%, respectively). Because low-
malignant-potential ovarian cancer may be etiologically dis-
tinct from invasive cancer (14, 15), we focused the remainder
of our analyses on invasive disease. Among invasive cases,
the most important histologic differences were that tumors in
African Americans were less likely to be clear-cell and more
likely to be of a histologic type other than the 4 primary types
(serous, endometrioid, mucinous, and clear-cell). African-
American women were more likely to be diagnosed with
higher-stage disease and somewhat less likely to have poorly
differentiated tumors, although the differences in grade were
not statistically significant.
Comparisons of risk factors for ovarian cancer among
African-American and white women are presented in Table 2.
Because age-matching was based on all cases but this anal-
ysis was restricted to invasive cases, who are on average
older than low-malignant-potential cases, the age distribu-
tion of the controls was slightly younger than that of the
cases.
In age-adjusted analyses, many of the major reproduc-
tive factors that have been associated with ovarian cancer
risk among white women were similarly related to risk
among African-American women. Women who were par-
ous, had a later age at last pregnancy, had used oral contra-
ceptives for 1 year or more, or had had a tubal ligation were
at reduced risk of invasive ovarian cancer; however, there
was not strong evidence of a linear relation with number of
pregnancies for African-American women. History of in-
fertility or endometriosis was associated with a signifi-
cantly increased risk for white women and a modestly
but not significantly increased risk for African-American
women. Family history of breast or ovarian cancer in
a first-degree relative was associated with increased risk
in both racial/ethnic groups, with a stronger association
among African Americans. Later age at menarche and his-
tory of ever breastfeeding were associated with reduced
risk in white women, whereas no association was observed
among African Americans. Analyses of anthropometric
characteristics suggested that taller height and BMI 35
may be associated with risk among African-American
women but not among white women.
In multivariable models (Table 3), results were generally
similar to those observed in the age-adjusted models. The
association with age at menarche 12 years appeared to
differ by race/ethnicity, with an odds ratio of 1.30 (95%
confidence interval (CI): 0.67, 2.53) for African Americans
rather than the expected inverse association. The strength of
the association with family history of breast or ovarian can-
cer also appeared to differ by race/ethnicity. P values for the
interaction terms were 0.032 for race/ethnicity 3 family
history and 0.068 for race/ethnicity 3 age at menarche. In
models limited to parous women that included all of the
variables in Table 3 plus history of breastfeeding, white
women who had breastfed had a nonsignificantly reduced
risk (odds ratio ¼ 0.83, 95% CI: 0.65, 1.06), whereas there
was no suggestion of a protective effect among African-
American women (odds ratio ¼ 1.09, 95% CI: 0.57, 2.07).
In addition to some differences between African Americans
and whites in the magnitude of associations with certain risk
factors, there were marked racial/ethnic differences in the
prevalences of a number of risk factors considered. For
example, prevalences in African-American and white con-
trols, respectively, were 29% and 18% for age at menarche
less than 12 years, 6% and 10% for nulligravidity, 51% and
33% for tubal ligation, and 51% and 26% for BMI 30
(Table 3). We therefore hypothesized that the relative con-
tribution of established risk factors for ovarian cancer could
vary considerably between African Americans and whites.
To address this, we calculated population attributable frac-
tions for the potentially modifiable risk factors of pregnancy,
oral contraceptive use, BMI, and tubal ligation. As Table 4
shows, the attributable fractions for not having a tubal liga-
tion, high BMI, and no oral contraceptive use were consid-
erably higher for African Americans than for whites,
reflecting the stronger associations and/or higher prevalence
of these factors among African Americans.
DISCUSSION
Our analyses of ovarian cancer risk factors in African-
American and white women show similar relations for sev-
eral characteristics, including inverse associations with
parity, oral contraceptive use, and tubal ligation, but there
are also suggestions of racial/ethnic differences in either the
direction or the magnitude of association for other risk fac-
tors. History of breastfeeding and later age at menarche were
both associated with reduced risk among whites, whereas
these associations were absent among African Americans.
Family history of breast or ovarian cancer was associated
with increased risk for both African Americans and whites,
but the association was considerably stronger for African-
American women. We considered the possibility that the
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stronger association in African-American women was due to
inaccurate reporting; however, the prevalences of a family
history of breast or ovarian cancer were very similar among
African-American and white controls, which argues against
there being differential reporting of family history across
racial/ethnic groups.
Although these observed racial/ethnic differences in the
magnitude or direction of associations with established
ovarian cancer risk factors are intriguing, the limitations
of our analyses must be acknowledged. The North Carolina
Ovarian Cancer Study included more African-American
women than any other study of ovarian cancer, but the rel-
atively small sample made it difficult to ascertain which
associations were true associations and which were chance
findings.
The modest sample size also precluded us from conduct-
ing analyses within subgroups defined by either menopausal
status or histologic type. Several reports have suggested that
reproductive risk factors and high BMI are more strongly
associated with premenopausal disease (16–23). However,
with only 38 premenopausal African-American cases in our
study population, analyses stratified by menopausal status
would not have yielded meaningful results. Similarly, the
sample was too small for us to explore differences in risk
factors by histologic subtype. The relatively small number
of African-American cases also led us to dichotomize some
Table 3. Odds Ratios for Invasive Epithelial Ovarian Cancer (Multivariable Logistic Regression Models) in African-








No. % No. % No. % No. %
Age, years (continuous
variable)
715 837 1.01 1.00, 1.02 106 181 1.00 1.00, 1.02
No. of pregnancies
0 114 15.9 84 10.0 1.00 Referent 14 13.2 11 6.1 1.00 Referent
1–2 306 42.8 332 39.7 0.66 0.47, 0.94 29 27.4 68 37.6 0.28 0.09, 0.86
3 295 41.3 421 50.3 0.46 0.32, 0.65 63 59.4 102 56.4 0.52 0.17, 1.62
Age at menarche, years
<12 172 24.1 151 18.0 1.00 Referent 26 24.5 52 28.7 1.00 Referent
12 543 75.9 686 82.0 0.65 0.50, 0.84 80 75.5 129 71.3 1.30 0.67, 2.53
Tubal ligation
No 535 74.8 561 67.0 1.00 Referent 73 68.9 89 49.2 1.00 Referent




Never use 233 34.1 225 27.6 1.00 Referent 45 43.3 55 32.0 1.00 Referent
<1 95 13.9 88 10.8 1.18 0.82, 1.69 15 14.4 14 8.1 1.89 0.73, 4.95
1–<5 162 23.7 222 27.2 0.78 0.58, 1.05 23 22.1 55 32.0 0.72 0.34, 1.53
5 193 28.3 281 34.4 0.73 0.54, 0.97 21 20.2 48 27.9 0.52 0.24, 1.15
Missing data 32 21 2 9
Family history of breast
or ovarian cancer
No 559 78.2 697 83.3 1.00 Referent 66 62.3 153 84.5 1.00 Referent
Yes 156 21.8 140 16.7 1.31 1.00, 1.72 40 37.7 28 15.5 2.73 1.45, 5.14
Body mass indexb 1 year
before diagnosis/
interview
<25 309 43.2 368 44.0 1.00 Referent 17 16.0 31 17.1 1.00 Referent
25–<30 211 29.5 254 30.3 0.92 0.71, 1.18 26 24.5 58 32.0 0.96 0.40, 2.30
30–<35 112 15.7 122 14.6 1.17 0.85, 1.61 22 20.8 43 23.8 1.32 0.53, 3.26
35 83 11.6 93 11.1 1.03 0.72, 1.47 41 38.7 49 27.1 1.52 0.65, 3.56
Abbreviations: CI, confidence interval; OR, odds ratio.
a Adjusted for all of the variables in the table.
b Weight (kg)/height (m)2.
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variables of interest in our analyses and dictated that we
limit the number of potential confounders evaluated in our
multivariable models. A larger sample would have afforded
us the opportunity to further explore the effects of the timing
and duration of oral contraceptive use and the timing of
pregnancies or tubal ligation.
Additional limitations of our analysis included those re-
lated to the case-control method. The possibility of bias being
introduced due to nonparticipation of ovarian cancer cases
and controls should be considered. Although we used rapid
case ascertainment to identify cases within 2 months of
diagnosis and the median time to case interview was 4.5
months, which should have minimized survival bias, there
is a possibility that cases who participated differed from those
who did not. When we compared the tumor characteristics of
ovarian cancer cases who were identified as eligible but did
not participate (because of death, lack of physician consent,
participant refusal, or inability to contact them) with the tu-
mor characteristics of cases who did participate, we found
that the proportion of invasive cases was slightly smaller
among participants than among nonparticipants. This is not
a surprising finding, given that cases who died quickly or for
whom physicians did not give consent were more likely to
have advanced disease. Among the invasive cases that were
the focus of most of our analyses, we found no statistically
significant differences in the proportions of higher-stage can-
cers between participants and nonparticipants. The racial/
ethnic differences in histologic type that we observed among
participants (i.e., a lower proportion of clear-cell tumors and
a higher proportion of tumors of ‘‘other’’ histologic types
among African Americans) were also observed among the
nonparticipating cases. Thus, the invasive cases enrolled in
the study appeared to be representative of the ovarian cancer
cases diagnosed in our catchment area.
Nonparticipation also has the potential to introduce bias if
participating cases and controls differ from persons who
decline to participate in the study. Although we had no risk
factor information on nonparticipants with which to assess
their similarity with women who participated in the study,
the associations we observed for white women within our
study population are consistent with established ovarian
cancer risk factors, which argues against our results’ being
biased due to nonparticipation.
Despite the limited sample of African-American women,
the descriptive characteristics of our population and the at-
tributable fraction analyses suggest that the relative impor-
tance of ovarian cancer risk factors may vary between
African Americans and whites because of the substantial
differences in the prevalence and strength of associations
with factors such as tubal ligation and obesity. Tubal liga-
tion, which had a stronger association with ovarian cancer
among African Americans and is considerably more com-
mon among African Americans in our study population as
well as in national surveys (6), could be an important
explanatory factor for the lower rates of ovarian cancer
among African Americans.
Obesity, which has shown modest associations with ovar-
ian cancer risk in the majority of studies (22, 24–26), may
be a considerably more important risk factor for African-
American women, as evidenced by the markedly higher
attributable fraction for obesity that we observed in our data.
Consistent with national statistics (12), our data showed
a much higher prevalence of obesity among African Amer-
icans than among whites. In particular, severe obesity
Table 4. Odds Ratios for Invasive Epithelial Ovarian Cancer and Population Attributable Fractions for Selected














ORa 95% CI AF
Tubal ligation
Yes 168 269 1.00 Referent 0.204 33 91 1.00 Referent 0.341
No 515 547 1.37 1.08, 1.73 71 81 2.00 1.15, 3.48
Body mass indexb
<30 494 611 1.00 Referent 0.030 42 86 1.00 Referent 0.209
30 183 205 1.12 0.89, 1.42 62 86 1.54 0.91, 2.62
Duration of oral contraceptive
use, years
1 355 503 1.00 Referent 0.119 44 103 1.00 Referent 0.245
<1 328 313 1.33 1.06, 1.67 60 69 1.74 0.99, 3.05
Ever being pregnant
Yes 575 734 1.00 Referent 0.052 91 164 1.00 Referent 0.079
No 108 82 1.49 1.06 2.08 14 8 2.43 0.88, 6.73
Abbreviations: AF, attributable fraction; CI, confidence interval; OR, odds ratio.
a Adjusted for all of the variables in the table, as well as age, age at menarche, family history of breast or ovarian
cancer, and breastfeeding.
b Weight (kg)/height (m)2.
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(BMI 35), which had a threefold higher prevalence among
African Americans than among whites in our study, may be
especially relevant as a risk factor for ovarian cancer among
African Americans. Some investigators have reported either
that associations between BMI and ovarian cancer risk were
present only for persons with very high BMIs or that the
relations were considerably stronger for women in the high-
est BMI categories (27, 28). Other investigators have found
that the association between obesity and ovarian cancer was
present only among premenopausal women or was much
stronger for premenopausal ovarian cancer than for post-
menopausal ovarian cancer (21, 22). Because the markedly
higher prevalence of obesity among African-American
women is apparent even among adults aged 20–39 years
(12), African-American women may be at higher risk for
ovarian cancer diagnosed at a younger age. This is consis-
tent with the higher proportion of premenopausal ovarian
cancer cases in African Americans as compared with whites
(34% vs. 26%) and the younger mean age at diagnosis (54.8
years vs. 57.4 years) that we observed in our population and
that has been reported in Surveillance, Epidemiology, and
End Results data (1). The younger age at diagnosis also may
be related to the stronger association with family history of
breast or ovarian cancer among African-American women,
which could be indicative of higher genetic risk.
Our data suggest that the relative importance of ovarian
cancer risk factors may vary between African-American and
white women because of differences in the prevalence of
and strength of associations with characteristics such as
tubal ligation, pregnancy, and obesity. However, conclu-
sions that can be drawn from our data are limited by the
small number of African Americans in our analysis, despite
our study population’s having more African-American
women than any other existing study of ovarian cancer.
Because ovarian cancer is a leading cause of cancer mortal-
ity in African Americans, there is a clear need for additional
studies in order to deepen our understanding of causative and
protective factors in this population.
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